ClinicalTrials.gg
RecruitingNCT07160179Updated Jul 13, 2026

Study to Assess the Adverse Events and How Intravitreal ABBV-6628 Moves Through the Body of Adult Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

A Phase 1/2 interventional study of ABBV-6628 and SYFOVRE in Geographic Atrophy and Age-Related Macular Degeneration, sponsored by AbbVie. Recruiting at 5 sites in United States. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-07-13.

Sponsored by AbbVie · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
66
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 131 studies in Geographic Atrophy with a site in United States — 35 open to participants now, 45 under way, 5 of them phase 3. Geographic Atrophy · United States.

Planned enrollment
60th of 107
66 · median 98
Started
2025
with 19 others
Phase 1/2
17 of 131
7 open now
Primary completion
2029-10
later than 39 of 44 live
Registered
115th of 131
by date

Among the 131 studies in Geographic Atrophy with a site in United States, this one is the 60th largest by planned enrollment of the 107 interventional ones that give a count, is one of 20 that started in 2025, is one of 17 in phase 1/2, reaches primary completion later than 39 of the 44 other live ones, and was the 115th registered.

Geographic Atrophy

188 studies on the registry are indexed under Geographic Atrophy; 52 are open to participants now.

Browse Geographic Atrophy studies →

Open to participants now

35 of the 131 studies in Geographic Atrophy with a site in United States are open now. Recruiting first, the newest first:

29 more — sign in →

All 35 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 40 Geographic Atrophy studies recruiting now, 31 (78%) set no upper age limit and none (0%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 131 studies in Geographic Atrophy with a site in United States, or all of them as a file.
02

Study summary

Age-related macular degeneration (AMD) is the abnormal growth of new blood vessels in the light-sensitive tissue at the back of the eye called the retina. Geographic Atrophy (GA) is an advanced form of dry AMD. The purpose of this study is to assess the adverse events and how intravitreal ABBV-6628 moves through the body of adult participants with secondary to age-related macular degeneration

ABBV-6628 is an investigational monoclonal antibody fragment being developed for the treatment of geographic atrophy (GA) secondary to (AMD) age-related macular degeneration. Participants in the Stage 1 part will be placed in 1 of 4 groups, called treatment arms. Participants in Stage 2 will be placed into 1 of 2 groups. Each group receives different treatment. Adult participants aged 50 and older years with a diagnosis GA secondary to age-related macular degeneration will be enrolled. Around 66 participants will be enrolled in the study at approximately 27 sites across the US.

Participants in Stage 1 will be given ABBV-6628 as an intravitreal injection (injection into the jelly-like tissue that fills the eyeball injection) with dose escalation. Participants in Stage 2 will receive ABBV-6628 or SYFOVRE, an approved treatment for geographic atrophy, administered as per the FDA-approved label. The treatment duration is approximately 22 months and 3 months of follow-up.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular weekly visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

03

Conditions studied

  • Geographic Atrophy
  • Age-Related Macular Degeneration

Keywords

  • Geographic Atrophy
  • Age-Related Macular Degeneration
  • ABBV-6628
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Stage 1 and Stage 2

-Diagnosed with Geographic atrophy (GA) secondary to age-related macular degeneration (AMD) in the study eye.

Stage 1

  • Foveal or non-foveal GA with total GA lesion area ≥ 0.5 DA (1.25 mm2) in the study eye, as assessed by the investigator at Screening and confirmed by the central reading center prior to Baseline/Day 1
  • Absence of choroidal neovascularization (CNV) in the study eye as assessed by the investigator at Screening and confirmed by the central reading center prior to Baseline/Day 1. In addition, investigators should confirm eligibility prior to treatment administration on Baseline/Day 1.

Stage 2

  • Non-foveal GA with total lesion area of 1 to 7 DA (2.5 to 17.5 mm2); within 0.5 to 1.5 mm from fovea center in the study eye, as assessed by the investigator at Screening and confirmed by the central reading center prior to Baseline/Day 1.
  • Absence of CNV in both eyes as assessed by the investigator at Screening and confirmed by the central reading center prior to Baseline/Day 1. In addition, investigators should confirm eligibility prior to treatment administration on Baseline/Day 1.

Exclusion criteria

Exclusion Criteria:

Stage 1 and Stage 2

  • History of recurrent or currently active ocular or intraocular inflammation (e.g., uveitis, endophthalmitis) in at least one eye at Screening and Baseline/Day 1.
  • Active periocular, ocular, or intraocular infection in at least one eye at Baseline/Day 1.
  • History or clinical signs of diabetic retinopathy, diabetic macular edema (DME), or any retinal vascular disease other than AMD in at least one eye at Screening and Baseline/Day 1.
05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
66 participants (estimated)

Study arms

  • Experimental
    ABBV-6628: Stage 1-Cohort 1

    Participants will receive a single dose of ABBV-6628 in Cohort 1 on day 1.

    Drug: ABBV-6628

  • Experimental
    ABBV-6628: Stage 1 -Cohort 2

    Participants will receive a single dose of ABBV-6628 in Cohort 2 on day 1.

    Drug: ABBV-6628

  • Experimental
    ABBV-6628: Stage 1 -Cohort 3

    Participants will receive a single dose of ABBV-6628 in Cohort 3 on day 1.

    Drug: ABBV-6628

  • Experimental
    ABBV-6628: Stage 1 -Cohort 4

    Participants will receive ABBV-6628 in Cohort 4 on day 1 and month 2.

    Drug: ABBV-6628

  • Experimental
    ABBV-6628: Stage 2

    Participants will receive ABBV-6628 for approximately 22 months followed by 3 months of follow-up.

    Drug: ABBV-6628

  • Experimental
    SYFOVRE: Stage 2

    Participants will receive SYFOVRE for approximately 22 months followed by 3 months of follow-up.

    Drug: SYFOVRE

Interventions

  • DrugABBV-6628

    Intravitreal injection

  • Intravitreal injection

06

What researchers measure

Primary outcomes

  1. Number of Participants Experiencing Adverse Events

    An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.

    Time frame: Up to approximately 25 months

  2. Number of Participants with Abnormal Change in Physical Examinations

    Number of participants with abnormal change in physical examinations in areas like cardiovascular, respiratory, gastrointestinal, and neurological systems will be assessed.

    Time frame: Up to approximately 25 months

  3. Number of Participants with Abnormal Change From Baseline in Vital Sign Measurements

    Number of participants with abnormal change from baseline in vital sign measurements like systolic and diastolic blood pressure will be assessed.

    Time frame: Up to approximately 25 months

  4. Change From Baseline in Electrocardiograms (ECGs)

    12-lead resting ECGs will be recorded. Parameters include heart rate, PR interval, QT interval, QRS duration, and QT interval corrected using Fridericia's formula (QTcF).

    Time frame: Up to approximately 25 months

  5. Number of Participants with Abnormal Change in Clinical Laboratory Test Results Like Hematology will be Assessed

    Number of participants with abnormal change in clinical laboratory test results like hematology will be assessed.

    Time frame: Up to approximately 25 months

  6. Change from baseline in Best Corrected Visual Acuity (BCVA)

    BCVA measured by Early Treatment Diabetic Retinopathy Study (ETDRS) (normal luminance and low luminance visual acuity)

    Time frame: Up to approximately 25 months

  7. Change in Slit lamp biomicroscopy assessment

    Changes in Slit lamp biomicroscopy assessed by the physician will be assessed.

    Time frame: Up to approximately 25 months

  8. Change in Intraocular pressure (IOP)

    Measured by using Goldmann applanation tonometry (GAT) or hand-held tonometer

    Time frame: Up to approximately 25 months

  9. Change in Lens examination assessment

    Changes in Lens examination assessed by the physician will be assessed.

    Time frame: Up to approximately 25 months

  10. Change in Ophthalmoscopy assessment

    Changes in Ophthalmoscopy assessed by the physician will be assessed.

    Time frame: Up to approximately 25 months

  11. Change in fundus autofluorescence (FAF) imaging assessed by Investigator

    Fundus autofluorescence (FAF) imaging assessed by Investigator

    Time frame: Up to approximately 25 months

  12. Change in Retinal evaluation

    Measured by color fundus photography (CFP) imaging assessed by Investigator

    Time frame: Up to approximately 25 months

  13. Change in spectral domain optical coherence tomography (SD-OCT)

    Spectral domain optical coherence tomography (SD-OCT)

    Time frame: Up to approximately 25 months

  14. Change in Fluorescein angiography (FA) assessed by Investigator.

    Fluorescein angiography (FA) assessed by Investigator

    Time frame: Up to approximately 25 months

  15. Change in choroidal neovascularization (CNV) assessed by Investigator.

    Choroidal Neovascularization (CNV) assessed by Investigator.

    Time frame: Up to approximately 25 months

  16. Percentage of Participants with Clinically Significant Post-treatment Administration Assessment (study eye only) Findings as Assessed by the Investigator

    Post-treatment Administration Assessment (study eye only)

    Time frame: Up to approximately 25 months

  17. Maximum Serum Concentration (Cmax) of ABBV-6628

    Cmax of ABBV-6628

    Time frame: Up to approximately 25 months

  18. Time to Cmax (Tmax) of ABBV-6628

    Tmax of ABBV-6628

    Time frame: Up to approximately 25 months

  19. Area Under the Concentration-Time Curve From zero to the last measurable Timepoint (AUC0-Tlast) of ABBV-6628

    AUC0-Tlast of ABBV-6628

    Time frame: Up to approximately 25 months

  20. Stage 2-Trough serum concentration immediately before next dose (Ctrough) of ABBV-6628

    Ctrough of ABBV-6628

    Time frame: Up to approximately 12 months

07

Study locations

5 of 5 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2025 (actual). Primary completion is estimated for Oct 2029, 50 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 12, 2025
First posted
Sep 8, 2025
StartActual
Aug 13, 2025
Primary completionEst.
Oct 2029
CompletionEst.
Oct 2029
Last update
Jul 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07160179
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Sep 8, 2025
Start date
Aug 13, 2025
Primary completion
Oct 2029 (estimated)
Completion
Oct 2029 (estimated)
Last update
Jul 13, 2026

Study contacts

ABBVIE CALL CENTER
Contact
abbvieclinicaltrials@abbvie.com
844-663-3742
ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pegcetacoplan

Start the discussion